ALAUNOS THERAPEUTICS INC (TCRT) Stock Price & Overview

NASDAQ:TCRTUS98973P3091

Current stock price

3.15 USD
-0.11 (-3.37%)
Last:

The current stock price of TCRT is 3.15 USD. Today TCRT is down by -3.37%. In the past month the price increased by 26.85%. In the past year, price increased by 118.79%.

TCRT Key Statistics

52-Week Range1.3137 - 6.2
Current TCRT stock price positioned within its 52-week range.
1-Month Range2.5 - 3.7
Current TCRT stock price positioned within its 1-month range.
Market Cap
7.025M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.29
Dividend Yield
N/A

TCRT Stock Performance

Today
-3.37%
1 Week
-10.68%
1 Month
+26.85%
3 Months
-8.43%
Longer-term
6 Months +34.71%
1 Year +118.79%
2 Years -81.99%
3 Years -96.55%
5 Years N/A
10 Years N/A

TCRT Stock Chart

ALAUNOS THERAPEUTICS INC / TCRT Daily stock chart

TCRT Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TCRT. When comparing the yearly performance of all stocks, TCRT is one of the better performing stocks in the market, outperforming 93.4% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TCRT Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TCRT. While TCRT seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TCRT Earnings

Next Earnings DateMar 30, 2026
Last Earnings DateNov 12, 2025
PeriodQ3 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

TCRT Forecast & Estimates


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y243.33%
Revenue Next YearN/A

TCRT Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

TCRT Financial Highlights

Over the last trailing twelve months TCRT reported a non-GAAP Earnings per Share(EPS) of -2.29. The EPS decreased by -14.06% compared to the year before.


Income Statements
Revenue(TTM)6.00K
Net Income(TTM)-4.03M
Industry RankSector Rank
PM (TTM) N/A
ROA -108.08%
ROE -143.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%24.57%
Sales Q2Q%N/A
EPS 1Y (TTM)-14.06%
Revenue 1Y (TTM)0%

TCRT Ownership

Ownership
Inst Owners6.36%
Shares2.23M
Float2.12M
Ins Owners4.93%
Short Float %1.62%
Short Ratio1.62

TCRT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.01391.561B
AMGN AMGEN INC16.02197.434B
GILD GILEAD SCIENCES INC16.37180.267B
VRTX VERTEX PHARMACEUTICALS INC23.89118.403B
REGN REGENERON PHARMACEUTICALS16.3880.021B
ALNY ALNYLAM PHARMACEUTICALS INC42.6942.294B
INSM INSMED INC N/A31.169B
NTRA NATERA INC N/A28.017B
BIIB BIOGEN INC11.5226.895B
UTHR UNITED THERAPEUTICS CORP17.8923.418B
MRNA MODERNA INC N/A21.054B
EXAS EXACT SCIENCES CORP341.9519.824B
RVMD REVOLUTION MEDICINES INC N/A19.619B

About TCRT

Company Profile

TCRT logo image Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.

Company Info

IPO: 2004-08-20

ALAUNOS THERAPEUTICS INC

501 E Las Olas Blvd, Suite 300

FORT LAUDERDALE FLORIDA US

Employees: 1

TCRT Company Website

TCRT Investor Relations

Phone: 13463554099

ALAUNOS THERAPEUTICS INC / TCRT FAQ

What does ALAUNOS THERAPEUTICS INC do?

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Fort Lauderdale, Florida and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The firm is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The firm has not generated any revenues.


Can you provide the latest stock price for ALAUNOS THERAPEUTICS INC?

The current stock price of TCRT is 3.15 USD. The price decreased by -3.37% in the last trading session.


Does TCRT stock pay dividends?

TCRT does not pay a dividend.


What is the ChartMill rating of ALAUNOS THERAPEUTICS INC stock?

TCRT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the sector and industry classification for ALAUNOS THERAPEUTICS INC?

ALAUNOS THERAPEUTICS INC (TCRT) operates in the Health Care sector and the Biotechnology industry.


Can you provide the number of employees for ALAUNOS THERAPEUTICS INC?

ALAUNOS THERAPEUTICS INC (TCRT) currently has 1 employees.